Our diagnostic platform is driven by discovery of tumor-derived QSOX1-L biomarker in blood. QSOX1-L biomarker is not present, or present at low levels in healthy individuals. Quantitative tests that detect QSOX1-L will determine if levels correlate with i)stage of disease, ii) recurrence of disease and/or iii) response to therapy.
For the table below, everything is in pre-clinical development.
COMPANION DIAGNOSTIC TEST
AXIM has developed proprietary assays for detection of QSOX1-L in patients undergoing cancer treatment. In the third quarter of 2020, AXIM will contract with Translational Drug Development, LLC (TD2) to conduct human xenograft studies of TNBC in mice so that pre-clinical studies in animals will determine if QSOX1-L can be used as a biomarker that predicts increasing or decreasing tumor burden. Plasma samples from mice will be tested with our point-of-care QSOX1-L detection assay.
IMMUNOHISTOCHEMISTRY (IHC) DIAGNOSTIC TEST
Using antibodies developed in house or licensed from Dr. Lake’s laboratory at ASU and Mayo Clinic, IHC will be developed to help pathologists identify tumor cells, thereby diagnosing cancer, in body fluids and tissue biopsies.